We use cookies for a better user experience. Read our Privacy Policy

I Agree

Radiopharmaceuticals Market Forecast Report, 2021-2031

Radiopharmaceuticals Market (Compound: Fluorine-18 Derivatives, Technetium-99, Lutetium [Lu] 177, Gallium-68, Zirconium 89, 11C-choline, 14C-urea, and Others; System: PET and SPECT; Indication: Oncology, Neurology, Cardiology, and Others; and End-user: Hospitals, Diagnostic Labs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021 - 2031

On the basis of end-use application, the global radiopharmaceuticals market is divided into two different types, including diagnostic centers and hospitals. Due to substantial availability of competent medical practitioners in hospital radiology departments, hospitals segment is expected to hold considerable share of this market during the forecast period. However, the growing number of diagnostic centers, particularly in developed nations such as the U.S. is likely to propel the global radiopharmaceuticals market forward over the forecast period, from 2021 to 2031

Radiopharmaceuticals are a class of radioactive substances that can be employed for diagnostic or therapeutic purposes. Chemicals that emit beta particles (positrons or electrons) or gamma rays are often employed for diagnostic purposes, whereas compounds that release Auger electrons or alpha particles are typically utilized for therapeutic purposes. Radiopharmaceuticals are referred to as "tracers" when they are utilized for diagnostic reasons. The quantity of radiation in diagnostic radiopharmaceuticals is lower than in therapy radiopharmaceuticals.

Radiopharmaceuticals are basically unique therapeutic compositions that incorporate radioisotopes. These radiopharmaceuticals are utilized for both diagnosis and treatment. Radiopharmaceuticals are classified into four different categories, which are radiopharmaceutical preparation, radionuclide generator, radiopharmaceutical precursor, and radiopharmaceutical preparation kit.

To know th escope of our report Get a Sample on Radiopharmaceutical Market

Rise in Research and Development Activities is Expected to Drive Demand in the Market

The global radiopharmaceuticals market is driven by the rise in patient awareness, demand for precise diagnosis, increasing demand for disease-targeted cancer therapy, and the growing uses of molecular imaging. The utilization of monoclonal antibodies and radiolabeled peptides for the identification and treatment of malignant tumors (referred to as radiopharmaceutical based customized therapy) is likely to fuel growth of the global Radiopharmaceuticals Market. The market research report examines the radiopharmaceutical sector in further depth, offering a comprehensive view of market dynamics, patient preferences, illness trends, and supply and demand.

In the last few decades, nuclear medicine has acquired a lot of popularity. The availability of 99m Tc, an isotope used in 80% of diagnostic procedures, is primarily responsible for nuclear medicine's expanding popularity. At present, about 25 million diagnostic procedures involving 99m Tc radiopharmaceuticals are performed yearly, with trends indicating that this number is likely to rise. The availability of short-lived 99m Tc is one of the key factors likely to drive the adoption of Technetium 99. At present, research and development operations are in full swing to boost 99 Mo's total production capacity, which is expected to have a beneficial influence on 99m Tc output.

Get a glimpse of the in-depth analysis through our Report Brochure

In the current situation, 99m Tc is widely employed in a variety of diagnostic procedures, such as neuroendocrine tumor imaging and thyroid uptake pertechnetate. In the last few years, there has been a tremendous increase in research activity aimed at developing new and better 99m Tc radiopharmaceuticals. 99m Tc is predicted to dominate the global radiopharmaceutical market throughout the forecast timeframe, from 2021 to 20321,as applications of 99m Tc for dynamic and morphological imaging of the liver, kidneys, and bone are expected to rise. In addition, due to their widespread availability and low prices, various radiopharmaceuticals are expected to gain popularity.

radiopharmaceutical market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Increasing Demand for Risk Assessment Services for Cancer Treatment to Drive North America and Europe Markets

North America, Latin America, Asia Pacific, Europe, and Middle East and Africa are the four primary regions that make up the global radiopharmaceuticals market. In 2020, the global radiopharmaceuticals market was headed by North America, trailed by Europe. Due to a rise in PET-CT scanner equipment installations and increased demand for disease risk assessment services for cancer treatment, North America held a large part of the global radiopharmaceuticals market in 2020. From 2021 to 2031, the radiopharmaceuticals market in Asia Pacific is expected to rise at a rapid growth rate. The radiopharmaceuticals market in the region is expected to be driven by product launches, acquisitions, distribution agreements, partnerships, and regional growth by local companies, particularly in India and China.

Radiopharmaceuticals Market - Segmentation

TMR’s study on the global radiopharmaceuticals market includes information divided into five segments: compound, indication, system, end-user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global radiopharmaceuticals market have been discussed in detail.

Compound
  • Fluorine-18 derivatives
    • Fluorine-18 Fludeoxyglucose (FDG)
    • Fluorine-18 Sodium Fluoride
    • Fluorine-18 Flucicovine
    • Fluorine-18 Florbetapir
    • Fluorine-18 Florbetaben
    • Others
  • Technetium-99
  • Lutetium (Lu) 177
  • Gallium-68
    • Dotatate
    • Dotatoc
  • Zirconium 89
  • 11C-choline
  • 14C-urea
  • Others
System
  • PET
    • Standalone PET Systems
    • Hybrid PET/CT
    • Hybrid PET/MRI
  • SPECT
Indication
  • Oncology
  • Neurology
    • Neurodegenerative Diseases (AD, PD, and Others)
    • Epilepsy
  • Cardiology
  • Others
End-user
  • Hospitals
  • Diagnostic Labs
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
Radiopharmaceuticals Market Forecast Report, 2021-2031

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of Radiopharmaceuticals Market?

The radiopharmaceuticals market is projected to reach a value of US$ 8.5 Bn by 2031 end

What will be the forecast period in the Radiopharmaceuticals Market report?

The Forecast period considered for the Radiopharmaceuticals Market is 2021 - 2031

What is the anticipated CAGR of the Radiopharmaceuticals Market in the forecast period?

The radiopharmaceuticals market is anticipated to grow at a CAGR of 7.3% during the forecast period

What are the end-use segments in the Radiopharmaceuticals Market?

The end-use segments in radiopharmaceuticals market are hospitals, diagnostic labs, and others

Which is the rising prominent segment in the Radiopharmaceuticals Market?

The tc-99 segment is anticipated to account for major share of the global radiopharmaceuticals market by 2031

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceuticals Market

4. Market Overview

    4.1. Introduction & Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities

    4.3. Global Radiopharmaceuticals Market Analysis and Forecast, 2017–2031

5. Market Outlook

    5.1. COVID-19 Pandemics Impact on Industry

    5.2. Key Industry Events

    5.3. No. of Nuclear Medicine Centers in Major Countries

    5.4. List of FDA Approved Radioisotopes

6. Global Radiopharmaceuticals Market Analysis and Forecast, by Compound

    6.1. Introduction & Definition

    6.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

        6.2.1. Fluorine-18 Derivatives

            6.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

            6.2.1.2. Fluorine-18 Sodium Fluoride

            6.2.1.3. Fluorine-18 Flucicovine

            6.2.1.4. Fluorine-18 Florbetapir

            6.2.1.5. Fluorine-18 Florbetaben

            6.2.1.6. Others

        6.2.2. Technetium-99

        6.2.3. Lutetium (Lu) 177

        6.2.4. Gallium-68

            6.2.4.1. Dotatate

            6.2.4.2. Dotatoc

        6.2.5. Zirconium 89

        6.2.6. 11C-choline

        6.2.7. 14C-urea

        6.2.8. Others

    6.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Compound

7. Global Radiopharmaceuticals Market Analysis and Forecast, by Indication

    7.1. Introduction & Definition

    7.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

        7.2.1. Diagnosis

        7.2.2. Neurology

            7.2.2.1. Neurodegenerative Disease (AD, PD, and Others)

            7.2.2.2. Epilepsy

        7.2.3. Cardiology

        7.2.4. Others

    7.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Indication

8. Global Radiopharmaceuticals Market Analysis and Forecast, by System

    8.1. Introduction & Definition

    8.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

        8.2.1. PET

            8.2.1.1. Standalone PET systems

            8.2.1.2. Hybrid PET/CT

            8.2.1.3. Hybrid PET/MRI

        8.2.2. SPECT

    8.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by System

9. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user

    9.1. Introduction & Definition

    9.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        9.2.1. Hospitals

        9.2.2. Diagnostic Labs

        9.2.3. Others

    9.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by End-user

10. Global Radiopharmaceuticals Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Rest of the World

    10.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Region

11. North America Radiopharmaceuticals Market Analysis and Forecast

    11.1. Introduction

    11.2. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

        11.2.1. Fluorine-18 Derivatives

            11.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

            11.2.1.2. Fluorine-18 Sodium Fluoride

            11.2.1.3. Fluorine-18 Flucicovine

            11.2.1.4. Fluorine-18 Florbetapir

            11.2.1.5. Fluorine-18 Florbetaben

            11.2.1.6. Others

        11.2.2. Technetium-99

        11.2.3. Lutetium (Lu) 177

        11.2.4. Gallium-68

            11.2.4.1. Dotatate

            11.2.4.2. Dotatoc

        11.2.5. Zirconium 89

        11.2.6. 11C-choline

        11.2.7. 14C-urea

        11.2.8. Others

    11.3. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

        11.3.1. Diagnosis

        11.3.2. Neurology

            11.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

            11.3.2.2. Epilepsy

        11.3.3. Cardiology

        11.3.4. Others

    11.4. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

        11.4.1. PET

            11.4.1.1. Standalone PET systems

            11.4.1.2. Hybrid PET/CT

            11.4.1.3. Hybrid PET/MRI

        11.4.2. SPECT

    11.5. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        11.5.1. Hospitals

        11.5.2. Diagnostic Labs

        11.5.3. Others

    11.6. North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America PET-CT Scanner Devices Market Attractiveness Analysis

        11.7.1. By Compound

        11.7.2. By Indication

        11.7.3. By System

        11.7.4. End-user

        11.7.5. By Country

12. Europe Radiopharmaceuticals Market Analysis and Forecast

    12.1. Introduction

    12.2. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

        12.2.1. Fluorine-18 Derivatives

            12.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

            12.2.1.2. Fluorine-18 Sodium Fluoride

            12.2.1.3. Fluorine-18 Flucicovine

            12.2.1.4. Fluorine-18 Florbetapir

            12.2.1.5. Fluorine-18 Florbetaben

            12.2.1.6. Others

        12.2.2. Technetium-99

        12.2.3. Lutetium (Lu) 177

        12.2.4. Gallium-68

            12.2.4.1. Dotatate

            12.2.4.2. Dotatoc

        12.2.5. Zirconium 89

        12.2.6. 11C-choline

        12.2.7. 14C-urea

        12.2.8. Others

    12.3. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

        12.3.1. Diagnosis

        12.3.2. Neurology

            12.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

            12.3.2.2. Epilepsy

        12.3.3. Cardiology

        12.3.4. Others

    12.4. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

        12.4.1. PET

            12.4.1.1. Standalone PET systems

            12.4.1.2. Hybrid PET/CT

            12.4.1.3. Hybrid PET/MRI

        12.4.2. SPECT

    12.5. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        12.5.1. Hospitals

        12.5.2. Diagnostic Labs

        12.5.3. Others

    12.6. Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Radiopharmaceuticals Market Attractiveness Analysis

        12.7.1. By Compound

        12.7.2. By Indication

        12.7.3. By Systems

        12.7.4. By End-user

        12.7.5. By Country/Sub-region

13. Asia Pacific Radiopharmaceuticals Market Analysis and Forecast

    13.1. Introduction

    13.2. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

        13.2.1. Fluorine-18 Derivatives

            13.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

            13.2.1.2. Fluorine-18 Sodium Fluoride

            13.2.1.3. Fluorine-18 Flucicovine

            13.2.1.4. Fluorine-18 Florbetapir

            13.2.1.5. Fluorine-18 Florbetaben

            13.2.1.6. Others

        13.2.2. Technetium-99

        13.2.3. Lutetium (Lu) 177

        13.2.4. Gallium-68

            13.2.4.1. Dotatate

            13.2.4.2. Dotatoc

        13.2.5. Zirconium 89

        13.2.6. 11C-choline

        13.2.7. 14C-urea

        13.2.8. Others

    13.3. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

        13.3.1. Diagnosis

        13.3.2. Neurology

            13.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

            13.3.2.2. Epilepsy

        13.3.3. Cardiology

        13.3.4. Others

    13.4. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

        13.4.1. PET

            13.4.1.1. Standalone PET systems

            13.4.1.2. Hybrid PET/CT

            13.4.1.3. Hybrid PET/MRI

        13.4.2. SPECT

    13.5. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        13.5.1. Hospitals

        13.5.2. Diagnostic Labs

        13.5.3. Others

    13.6. Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis

        13.7.1. By Compound

        13.7.2. By Indication

        13.7.3. By Systems

        13.7.4. By End-user

        13.7.5. By Country/Sub-region

14. Rest of the World Radiopharmaceuticals Market Analysis and Forecast

    14.1. Introduction

    14.2. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

        14.2.1. Fluorine-18 Derivatives

            14.2.1.1. Fluorine-18 Fludeoxyglucose (FDG)

            14.2.1.2. Fluorine-18 Sodium Fluoride

            14.2.1.3. Fluorine-18 Flucicovine

            14.2.1.4. Fluorine-18 Florbetapir

            14.2.1.5. Fluorine-18 Florbetaben

            14.2.1.6. Others

        14.2.2. Technetium-99

        14.2.3. Lutetium (Lu) 177

        14.2.4. Gallium-68

            14.2.4.1. Dotatate

            14.2.4.2. Dotatoc

        14.2.5. Zirconium 89

        14.2.6. 11C-choline

        14.2.7. 14C-urea

        14.2.8. Others

    14.3. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

        14.3.1. Diagnosis

        14.3.2. Neurology

            14.3.2.1. Neurodegenerative Disease (AD, PD, and Others)

            14.3.2.2. Epilepsy

        14.3.3. Cardiology

        14.3.4. Others

    14.4. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

        14.4.1. PET

            14.4.1.1. Standalone PET systems

            14.4.1.2. Hybrid PET/CT

            14.4.1.3. Hybrid PET/MRI

        14.4.2. SPECT

    14.5. Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by End-user, 2017–2031

        14.5.1. Hospitals

        14.5.2. Diagnostic Labs

        14.5.3. Others

    14.6. Rest of the World Radiopharmaceuticals Market Attractiveness Analysis

        14.6.1. By Compound

        14.6.2. By Indication

        14.6.3. By System

        14.6.4. By End-user

15. Competition Landscape

    15.1. Company Profiles

        15.1.1. Advanced Accelerator Applications (a Novartis AG Company)

            15.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.1.2. Growth Strategies

            15.1.1.3. SWOT Analysis

        15.1.2. Siemens Healthineers AG

            15.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.2.2. Growth Strategies

            15.1.2.3. SWOT Analysis

        15.1.3. Jubilant Pharma Limited

            15.1.3.1. Company Overview (HQ, Business Segments)

            15.1.3.2. Growth Strategies

            15.1.3.3. SWOT Analysis

        15.1.4. GE Healthcare

            15.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.4.2. Growth Strategies

            15.1.4.3. SWOT Analysis

        15.1.5. Bayer AG

            15.1.5.1. Company Overview (HQ, Business Segments)

            15.1.5.2. Growth Strategies

            15.1.5.3. SWOT Analysis

        15.1.6. ITM Isotopen Technologien München AG

            15.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.6.2. Growth Strategies

            15.1.6.3. SWOT Analysis

        15.1.7. Telix Pharmaceuticals

            15.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.7.2. Growth Strategies

            15.1.7.3. SWOT Analysis

        15.1.8. Lantheus Holdings, Inc.

            15.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.8.2. Growth Strategies

            15.1.8.3. SWOT Analysis

        15.1.9. Eli Lilly and Company

            15.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.9.2. Growth Strategies

            15.1.9.3. SWOT Analysis

        15.1.10. Nihon Medi-Physics

            15.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.10.2. Growth Strategies

            15.1.10.3. SWOT Analysis

        15.1.11. Avanos Medical, Inc.

            15.1.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.11.2. Growth Strategies

            15.1.11.3. SWOT Analysis

List of Tables

Table 01: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Compound, 2017–2031

Table 02: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

Table 03: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Gallium-68, 2017–2031

Table 04: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

Table 05: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

Table 06: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 07: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

Table 08: Global Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 09: Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 10: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 11: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

Table 12: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

Table 13: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

Table 14: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

Table 15: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System (PET), 2017–2031

Table 16: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 17: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

Table 18: North America Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 19: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031 

Table 21: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

Table 22: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

Table 23: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

Table 24: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

Table 25: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 26: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

Table 27: Europe Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 28: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 29: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

Table 30: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

Table 31: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

Table 32: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

Table 33: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

Table 34: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 35: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

Table 36: Asia Pacific Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

Table 37: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

Table 38: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Fluorine-18 Derivatives, 2017–2031

Table 39: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Gallium-68, 2017–2031

Table 40: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by System, 2017–2031

Table 41: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by PET, 2017–2031

Table 42: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031

Table 43: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by Neurology, 2017–2031

Table 44: Rest of the World Radiopharmaceuticals Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Radiopharmaceuticals Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 02: Global PET-CT Scanner Devices Market Value Share, by Region, 2020

Figure 03: Global Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

Figure 04: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Technetium-99, 2017–2031

Figure 05: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Gallium-68, 2017–2031

Figure 06: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Fluorine-18 Derivatives, 2017–2031

Figure 07: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Lu-177, 2017–2031

Figure 08: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Zirconium89, 2017–2031

Figure 09: Global Radiopharmaceuticals Market Revenue (US$ Mn), by 11C-choline, 2017–2031

Figure 10: Global Radiopharmaceuticals Market Revenue (US$ Mn), by 14C-urea, 2017–2031

Figure 11: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017–2031

Figure 12: Global Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

Figure 13: Global Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

Figure 14: Global Radiopharmaceuticals Market Revenue (US$ Mn), by PET, 2017–2031

Figure 15: Global Radiopharmaceuticals Market Revenue (US$ Mn), by SPECT, 2017–2031

Figure 16: Global Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

Figure 17: Global Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

Figure 18: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Oncology, 2017–2031

Figure 19: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Cardiology, 2017–2031

Figure 20: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Neurology, 2017–2031

Figure 21: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017–2031

Figure 22: Global Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

Figure 23: Global Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

Figure 24: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Diagnostic Lab, 2017–2031

Figure 25: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Hospitals, 2017–2031

Figure 26: Global Radiopharmaceuticals Market Revenue (US$ Mn), by Others, 2017–2031

Figure 27: Global Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021 -2031

Figure 28: Global Radiopharmaceuticals Market Value Share Analysis, by Region, 2020 and 2031

Figure 29: Global Radiopharmaceuticals Market Attractiveness Analysis, by Region, 2021–2031

Figure 30: North America Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

Figure 31: North America Radiopharmaceuticals Market Value Share Analysis, by Country, 2020 and 2031

Figure 32: North America Radiopharmaceuticals Market Attractiveness Analysis, by Country, 2021–2031

Figure 33: North America Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

Figure 34: North America Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

Figure 35: North America Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

Figure 36: North America Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

Figure 37: North America Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

Figure 38: North America Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

Figure 39: North America Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

Figure 40: North America Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031 

Figure 41: Europe Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

Figure 42: Europe Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 43: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 44: Europe Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

Figure 45: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

Figure 46: Europe Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

Figure 47: Europe Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

Figure 48: Europe Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

Figure 49: Europe Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

Figure 50: Europe Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

Figure 51: Europe Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031

Figure 52: Asia Pacific Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

Figure 53: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 54: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 55: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

Figure 56: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

Figure 57: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

Figure 58: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

Figure 59: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

Figure 60: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031 

Figure 61: Asia Pacific Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

Figure 62: Asia Pacific Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031

Figure 63: Rest of the World Radiopharmaceuticals Market Value (US$ Mn) Forecast, 2017–2031

Figure 64: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by Compound, 2020 and 2031

Figure 65: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by Compound, 2021–2031

Figure 66: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by System, 2020 and 2031

Figure 67: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by System, 2021–2031

Figure 68: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by Indication, 2020 and 2031

Figure 69: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by Indication, 2021–2031

Figure 70: Rest of the World Radiopharmaceuticals Market Value Share Analysis, by End-user, 2020 and 2031

Figure 71: Rest of the World Radiopharmaceuticals Market Attractiveness Analysis, by End-user, 2021–2031 

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

695

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved